EMMA

Emmaus life sciences inc new

0.00 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Emmaus life sciences inc new stock is down -100% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.17% of the previous 23 February’s closed higher than January.

About Emmaus life sciences inc new

Emmaus Life Sciences, Inc. discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

  • Lisa Levin
    US crude oil futures traded sharply higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
  • Lisa Levin
    The Dow Jones closed higher by over 400 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
  • Lisa Levin
    US gold futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.